Clinical Trials Logo

Clinical Trial Summary

In this before-after study, different new methods for bacterial species identification from positive blood cultures will be compared towards historic controls. All samples are analyzed within the routine workflow for bacterial species identification and antibiotic resistance profiling. Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls) will be compared to patients from 2018 and 2019 with a new identification method (cases). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or Matrix-assisted Laser-Desorption/Ionization Time-of-Flight (MALDI-TOF MS). The new identification of positive blood cultures methods include (i) either the newly introduced Biofire FilmArray© Blood Culture Identification (BCID) panel or (ii) in a subset of patients whole genome sequencing (WGS) approaches.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04156633
Study type Observational
Source University Hospital, Basel, Switzerland
Contact
Status Active, not recruiting
Phase
Start date October 17, 2019
Completion date August 2022

See also
  Status Clinical Trial Phase
Completed NCT03869437 - RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI Phase 2
Terminated NCT02176122 - RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp. Phase 4
Completed NCT02437045 - Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response Phase 4
Completed NCT01576003 - Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants N/A